Wednesday, January 30, 2019

Market Outlook: Strategies To Conquer A Bear Market

A bear market can be your worst enemy or your best friend.
There are three approaches that you can employ to potentially capture enormous profit in this down market.
Which strategies you should take is strongly dependent on your own financial situation and temperament.
For indeed, the investor’s chief problem – and even his worst enemy – is likely to be himself. - Benjamin Graham
Most investors are highly enthusiastic when their stocks appreciate: nearly all investors can relate to that “warm feeling” when their portfolio lit up green during a bull market. Nevertheless, one has to conquer the bears in the middle a downturn in order to capture the profits of the subsequent bull market. In the thick of the recent downturn, the highly powerful human emotion that is fear exerts its detrimental effects. As investors do not easily forget the pain associated with blood spilling on Wall Street, fear usually induces investors to make impulsive decisions. That being said, we’d like to introduce the new Market Outlook series to help you navigate this time of uncertainty and high volatility.
As shown in Figure 1, all major market indices - NASDAQ Biotechnology Index (NASDAQ:NBI), SPDR S&P Biotech (NYSE:XBI), and Dow Jones Industrial Average (NYSE:DJI) - are trading on a downtrend. Back in 2018, we forecasted that the bear market will grow stronger in 2019. Interestingly, the bears came out of the woodwork after a brief rally in January this year. Except for a few trend breakers, most of the bioscience equities gave up a significant percentage of their recent gains. In our view, it’s quite likely that an overall negative sentiment has recently seized the market.
Figure 1: Macromarket analytics (Source: Yahoo finance)

Sunday, January 27, 2019

BioLife Solutions: An IBI Notable Community Discussion On January 25, 2019

Our Notable Community Discussion helped uncovered another potential big winner, BioLife Solutions.
BioLife Solution is a logistics provider for CAR-T and cell-based therapy innovation.
As CAR-T grows increasingly prominent, we expect that BioLife to enjoy much more robust profits.
Statement from the FDA is a good sign that the company, as well as other CAR-T innovators, will enjoy the upcoming industry tailwinds.
We appreciate the intelligence from bdymnsould and especially Stockfan1 that helped us learned about this company. We wish to share this discussion with all members.
Someone’s sitting in the shade today because someone planted a tree a long time ago. - Warren Buffett
We’d like to continue the weekend coverage with another Notable Community Discussion (“NCD”) article. The initial NCD article was on ResMed. As we stated in that article, the objective of this publication series is to provide additional context to the ongoing community discussion as well as to provide coverage for members who are unable to attend our daily discussion. In this piece, we’d like to present the market intelligence relating to BioLife Solution(NASDAQ:BLFS).
Figure 1: BioLife stock chart (Source: StockCharts)

About The Company

Based in Bothell Washington, BioLife Solution is an industry leader that focuses on the development and commercialization of logistics to service the innovators of cell and gene-based therapy like CAR-T. The company is powering by the proprietary hypothermic storage and cryopreservation freeze media. These biotechnologies maintain live cellular specimen in an environment that are protected by cold temperature and other excellent preservation materials.
Specifically, the HypoThermosol and CryoStor platforms are invaluable tools that has application in regenerative medicine, biobanking, and drug discovery. The biopreservation media is differentiated because it is pure and free from potential contaminants like proteins. The enhanced purity prevents samples from potential damage while improving their self-life and survivability. All that mentioned, we’ll dive into the insight shared by the financial guru and professor, bdymnsoul.

Monday, December 24, 2018

IBI Research On Industry Trends: Companion Diagnostics, Companion Biomarkers, And Liquid Biopsy To Power Precision Medicine

Individualized medicine is a new trend in medical management that has improved treatment outcomes.
Companion biomarkers and companion diagnostics are powering the aforesaid precision medicine.
As a tool associated with companion biomarkers and companion diagnostics, liquid biopsy is playing increasingly prominent roles over the traditional biopsy.
By 2022, the market for liquid biopsy and companion diagnostics are expected to grow to $17B and $6.5B, respectively.
We present an overview of this new industry trend in assisting readers to make your investment decision.
I never attempt to make money on the stock market. I buy on the assumption that they could close the market the next day and not reopen it for five years. - Warren Buffett
Image source:
Author's notes: In the spirit of the holiday, we'd like to share with all readers this research. If you wish to learn more about the specific companies that we mentioned in this article, we invite you to check out our private investment community, Integrated BioSci Investing.
As the Holiday is approaching, we’d like to share with all readers our Holiday Gift in showing our appreciation for your support. That being said, we’d like to share with you all our first Integrated BioSci Investing analysis on industry trends. As knowledge is power, we wish to empower readers with industry knowledge and novel developments. Our hope is that the market intelligence that we presented will better assist you in making your own informed investment decision. Accordingly, we’ll feature an overview of companion diagnostics, companion biomarkers, and liquid biopsy in this introductory research.

Saturday, September 15, 2018

More Benefits To IBI Members: New Research And Report Series To Assist Our Community


Specialty Research Series elucidates investment prospects in various markets (NASH, RNA-based medicines, CAR-T, genes therapy/editing, and infectious disease).
Educational Series explicates our investment philosophy for you to adapt to your own use.
Expert Interview Series features key opinion leaders and their best recommendations. Portfolio Review Series provides our latest takes on promising investments.
M&A Series reviews merger & acquisitions and forecasts potential outcomes. Sector Report Series analyzes industry headwinds and tailwinds.
Quality Improvement Series analyzes our mistakes to deliver better future returns. Development Series gives a sneak peek preview on our future direction.
We recently upgraded IBI with ongoing changes to improve the quality of our private research community. Accordingly, we improved our presentation on ways to best leverage on our research via a question and answer format. In this article, we’ll feature various research/report series with corresponding links to make it easy and efficient for you to conduct your own research due diligence. The aforesaid series include the following: Specialty Research, Educational, Expert Interview, M&A, Sector Report, Portfolio Review, Quality Improvement, and Development.

Specialty Research Series

We’ve featured a total of five different Specialty Research Series. The primary objective of the Specialty Research is to deliver in-depth analysis into a particular niche for investors who are interested in exploring only a particular field, for instance, the lucrative nonalcoholic steatohepatitis (“NASH”) market. Moreover, we discuss the latest medical breakthroughs in this series. Each article goes over the overall market opportunity, challenges, and investment prospects. For your convenience, we feature the links to five Specialty Research (on NASH, RNA-based medicines, CAR-T, genes therapy/editing, and infectious disease) as presented below.

Friday, February 23, 2018

Integrated BioSci Investing: CEO Abelardo Fraga To Transition Into The Role Of President Of Business Development


Abelardo Fraga (“AB”) currently serves as the CEO and Founder of the successful Brazilian firm, AFDatalink.
With wisdom in both business and investing, AB made the stellar calls like Atara Biotherapeutics that delivered over 224% profits for our community.
AB to join IBI as President of Business Development.
IBI to benefit from AB’s high quality thought-process as well as his market and business acumen.
The decades of experience as a top-level executive is the key growth catalyst to power IBI.
I am a better investor because I am a businessman, and I am a better businessman because I am an investor. - The Oracle of Omaha (Warren Buffett)
It is with great honor to introduce to Integrated BioSci Investing (“IBI”) partners, Abelardo Fraga who will join us as President of Business Development. Chief Executive Officer Fraga brings in decades of experience in high-level management as the Founder and CEO of AFDatalink (a Brazilian tech firm that focuses on electronics). Prior to founding AFDatalink, AB served as the Global Account Director for the prestigious firms, Motorola and Alcatel/Lucent Technologies and as a M&A consultant. Moreover, AB is trained in investment management at the University of Geneva-Switzerland as well as investment at Stanford University and the University of Omaha. Furthermore, AB also studied financial evaluation and strategy at the University Illinois at Urbana-Champaign.
Figure 1: Notable bioscience recommendations by CEO Abelardo Fraga (Source: Google Finance)

Saturday, February 10, 2018

An Integrated BioSci Investing Partners Reward Program: To Deliver Increasing Value For Subscribers


IBI Partners Reward program launched to increase the value for our subscribers.
Partners to earn points after staying with us for at least 3 months.
Points are rewarded for new subscriber referral. Quality stock tips and activity in the chat are also honored with points. Those who leave us a positive review also get points.
Points earned can be exchanged for cash monthly.
With certain milestones achieved, partners can gain entry into the VIP program.
Price is what you pay. Value is what you get. - The Oracle of Omaha (Warren Buffett)
Regardless of the tumultuous market this previous week, we’ve procured substantial gains for Integrated BioSci Investing (“IBI”) partners since 2017. If the bear market is to come, you’ll still continue to compound substantial capital if you have a long-term approach. With the 40% cash reserve in the IBI Long-Term portfolio, we’ll be in the position to take full advantage of the opportunities to purchase firms (on sales at significant discounts to their intrinsic values (if the recession will come soon).
Figure 1: Notable IBI performers. (Source: Google Finance)
Without further ado, let’s shift gear into the next growth catalyst. And, it is an honor to introduce you the Partners Reward (“PR”) Program - a new implementation that is seeking to deliver increasing value for our community of experts (physicians, scientists, fund managers, investment advisors, executives, market leaders, and everyday investors).
As follows, the program is based on a system that honors partners with points to be accumulated over time for rewards (including cash as well as the entry into our VIP Partnership). Later, we’ll go over how you can gain entry into the aforesaid VIP membership and how the cash conversion from points works. But first thing first, we’ll elucidate following ways for you to earn the points.

Subscribers Referral

With each new subscriber that you referred to IBI, you’ll receive 100 points. All you have to do is to reach out to your friends and family to subscribe to IBI. A good way is to advertise about us via your Facebook or other social media. Just make that you inform the new subscriber to let us know that you’re the person who made the referral. You can use your real name or pseudonym as you wish.

Loyalty Partners

By staying with us for at least three months, you’ll earn 100 points. For every 3 additional months, another 50 points will be added.

Market Intelligence

In addition, points will be rewarded to partners who are active in the chat forum (and to provide stellar stock tips as well as being helpful to the community). Of note, subscribers who tipped us with stock ideas that proved to work out over time will also rack up more points. Despite that the rewarding of this aspect can be subjective, we’ll try our best to make sure that it is fair to all partners. Accordingly, each reward in this category comes in as 100 points.

Business Development

Subscribers who provided us with insightful advice on business development as well as connecting us to various resources will also receive 100 points for each occasion. For instance, we’ll reward a partner with the pseudonym “8iron,” with 100 points, who helped us with the design of the IBI Long-Term portfolio. Moreover, those who wrote us a positive review (to enable investors to learn more about our service) will be rewarded with 100 points.

Partner of The Month

A subscriber who earned the most points for the month will be featured in our “Partner of The Month.” In this case, we’ll give you an additional 1,000 points on top of what you’ve earned.

Points Conversion

With the points accumulation over time, you can cash out monthly. If you choose to cash out, we simply need to have your PayPal for us to send you money within a day of your request. We can also send money via MoneyGram, but we prefer PayPal. In terms of conversion, every 100 points are worth $10. For 20K points accumulated, you can cash out your $2K or trade it for the entry into the aforesaid VIP Program.
VIP Partners have the best service, hands down. As a VIP, you can consult with Dr. Tran as much as you like. You’ll have his cell phone as well as Skype. And, he will feature your favorite stocks in the Integrated BioSci research, which often helps to unlock its value of your holding substantially. Nevertheless, the stocks have to meet certain criteria. You’ll also get periodic exclusive intelligence not available to regular members. Furthermore, you’ll gain the first invitation to join IBI’s management team.

Transparency And Tracking

We’ll keep a Google Spreadsheet that is viewable with a password. All you have to do is to provide us your email (and we’ll send you an email invitation for access. Notably, you can check your progress in real-time (as well as to chat with us and let us know what else we can do to better serve you).

Final Remarks

We’re testing this new PR Program to assess its efficacy in delivering increasing value for our partners. Of note, we’ll honor the points with the cash as stated. Be that as it may, we wish to disclaim that the points do not have cash value and are subject to change anytime on our behalf without due notice. Last but not least, we’ll update this program based on your feedback. Let us know what you think. As you are our business partners, your voice is important to us.
Author’s Notes: We’re honored that you took the time out of your busy day to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI”) marketplace research is delivering stellar returns since inceptions. To name a few, Nektar Therapeutics (NASDAQ:NKTR) procured more than 359% profits; Spectrum Pharmaceuticals (NASDAQ:SPPI) delivered over 167% gains; Kite Pharma netted 82%; Atara Biotherapeutics (NASDAQ:ATRA) appreciated +211%. Crispr Therapeutics (NASDAQ:CRSP) garned plus 110%. Exelixis Inc (NASDAQ:EXEL) earned greater than 51% capital appreciation. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios.
Notably, we’ll increase our price soon. SUBSCRIBE to our marketplace research now to lock in the legacy price and save money in the future.To receive real-time alerts on our articles as well as blogs, be sure to check out our profile page and CLICK the orange FOLLOW button . Asides the exclusivities, this article is the truncated version of the research we published in advance to IBI subscribers. Further, you can read up on Dr. Tran’s background by following this link. If you'd like to get our other once weekly ideas sent to your mailbox, check out Dr. Tran BioSci and sign up with our mailing list.

Thursday, February 8, 2018

An Integrated BioSci Alpha Intelligence On Gilead Sciences: What the Fiscal 2017 Earning Foretells?


Gilead reported favorable Q4 earnings that beat the market’s average estimate. HCV revenue is still in a downtrend.
As Sovaldi’s entry into China to take root, sales should be improved.
Progress is being made in the NASH segment.
CAR-T is progressing robustly as we anticipated.
To push for robust growth in the coming years, the company is in discussions to potentially acquire a gene-editing company.
However, to all this should be added something of equal importance if an investment is to prove a genuine bonanza. The largest profits in the investment field go to those who are capable of correctly zigging when the financial community is zagging. The Father of Growth Investing (Philip Fisher)
On Feb. 7, 2018, Gilead Sciences (NASDAQ:GILD) - a giant bioscience at the forefront of the innovation and commercialization of therapeutics to service various niche markets - traded $2.38 (+2.9%) higher at $82.76 (due to the positive earnings). Since we recommended the firm to subscribers of Integrated BioSci Investing (on Nov. 10, 2017), the stock has appreciated more than 12%. The capital gain is mostly due to the following powerful catalysts powering the company: Chimeric Antigen Receptor and T-Cell Receptor (“CAR-T”) platform, Hepatitis C franchise expansion into the vast China market, as well as nonalcoholicsteatohepatitis (“NASH”).
Figure 1: Gilead stock chart. (Source: StockCharts).